Quantumcyte

Quantumcyte is a private, early-revenue stage company operating in the diagnostics and cell therapy sectors with a focus on precision medicine sample preparation. Its core technology, the QCPRECISE™ platform, is an automated system that uses digital pathology annotations to physically mask and then selectively lyse specific cellular regions from tissue slides, yielding highly enriched samples for molecular testing. The platform is positioned to address critical bottlenecks in both clinical diagnostics—by reducing test failures from low-tumor-content biopsies—and pharmaceutical R&D—by accelerating biomarker discovery. Early adopters include Singapore General Hospital and unnamed top-tier pharmaceutical companies.

The QCPRECISE™ platform is an integrated system that connects digital pathology annotations with physical tissue extraction. It uses software to align annotations, a polymer printing process to mask non-target areas, and proprietary chemistry to selectively lyse and harvest only the annotated Regions of Interest (ROI) from tissue slides, producing high-purity lysates for genomics, transcriptomics, and proteomics.

Quantumcyte competes with traditional manual and laser capture microdissection (LCM) systems, which are slower, less automated, and can have lower throughput. It also faces competition from high-plex spatial biology platforms (e.g., from 10x Genomics, NanoString, Akoya) that analyze tissue in situ but often at higher cost and with different output data. Quantumcyte's differentiation lies in its focus on high-purity extraction for standard bulk omics, automation, and integration with existing pathology workflows.